Rein Therapeutics Valuation Multiples

Rein Therapeutics Overview

About Rein Therapeutics

Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03: a peptide for which company conducted a Phase 1b dose-ranging, placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis; LTI-01: proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment; and LTI-05 and others.

Founded

2001

HQ

Employees

11

Website

reintx.com

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: —

Net Income: ($53M)

EV

$26M

Valuation Multiples

Multiples.vc

Start free trial

Rein Therapeutics Financials

Rein Therapeutics reported last 12-month revenue of —.

In the same LTM period, Rein Therapeutics generated — in gross profit and had net loss of ($53M).

Rein Therapeutics P&L

In the most recent fiscal year, Rein Therapeutics reported revenue of — and EBITDA of ($22M).

Rein Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX

Rein Therapeutics Stock Performance

Rein Therapeutics has current market cap of $43M, and enterprise value of $26M.

Rein Therapeutics' stock price is $1.53.

Rein Therapeutics Valuation Multiples

Rein Therapeutics trades at (1.2x) EV/EBITDA.

Rein Therapeutics Financial Valuation Multiples

As of April 11, 2026, Rein Therapeutics has market cap of $43M and EV of $26M.

Equity research analysts estimate Rein Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Rein Therapeutics has a P/E ratio of (0.8x).

Rein Therapeutics Margins & Growth Rates

Rein Therapeutics' revenue in the last fiscal year grew by —.

Rein Therapeutics' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $2.0M for the same period.

Rein Therapeutics Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Rein Therapeutics M&A Activity

Rein Therapeutics acquired XXX companies to date.

Last acquisition by Rein Therapeutics was on XXXXXXXX, XXXXX. Rein Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Rein Therapeutics Investment Activity

Rein Therapeutics invested in XXX companies to date.

Rein Therapeutics made its latest investment on XXXXXXXX, XXXXX. Rein Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).